Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Midazolam 10mg/2ml solution for injection ampoules
1501041T0AAAAAA
|
Midazolam hydrochloride | Midazolam hydrochloride | Anaesthesia | 71,261 |
|
Lidocaine 20mg/2ml (1%) solution for injection ampoules
1502010J0AABUBU
|
Lidocaine hydrochloride (Local Anaesthesia) | Lidocaine hydrochloride | Anaesthesia | 68,466 |
|
Emla 5% cream
1502010J0BEAABY
|
Emla | Lidocaine hydrochloride | Anaesthesia | 61,905 |
|
Lidocaine 700mg medicated plasters
1502010J0AAELEL
|
Lidocaine hydrochloride (Local Anaesthesia) | Lidocaine hydrochloride | Anaesthesia | 33,568 |
|
Instillagel gel
1502010J0BDAABQ
|
Instillagel | Lidocaine hydrochloride | Anaesthesia | 29,019 |
|
Lidocaine 40mg/2ml (2%) solution for injection ampoules
1502010J0AABEBE
|
Lidocaine hydrochloride (Local Anaesthesia) | Lidocaine hydrochloride | Anaesthesia | 28,268 |
|
Lidocaine 50mg/5ml (1%) solution for injection ampoules
1502010J0AABDBD
|
Lidocaine hydrochloride (Local Anaesthesia) | Lidocaine hydrochloride | Anaesthesia | 24,917 |
|
Glycopyrronium bromide 200micrograms/1ml inj ampoules
1501030G0AAAAAA
|
Glycopyrronium brom (Pre-med) | Glycopyrronium bromide | Anaesthesia | 24,296 |
|
Ralvo 700mg medicated plasters
1502010J0BWAAEL
|
Ralvo (Lidocaine hydrochloride) | Lidocaine hydrochloride | Anaesthesia | 19,143 |
|
Lidocaine 5% ointment
1502010I0AAAEAE
|
Lidocaine (Local Anaesthesia) | Lidocaine | Anaesthesia | 13,591 |
|
Lidocaine 2.5% / Prilocaine 2.5% cream
1502010J0AABYBY
|
Lidocaine hydrochloride (Local Anaesthesia) | Lidocaine hydrochloride | Anaesthesia | 11,005 |
|
Lidocaine 100mg/5ml (2%) solution for injection ampoules
1502010J0AACBCB
|
Lidocaine hydrochloride (Local Anaesthesia) | Lidocaine hydrochloride | Anaesthesia | 9,091 |
|
Lignospan Special 20mg/ml / 12.5micrograms/ml inj 2.2ml cart
1502010J0BTAACQ
|
Lignospan Special | Lidocaine hydrochloride | Anaesthesia | 8,234 |
|
Xylocaine 1% with Adrenaline 100microg/20ml inj vials
1502010J0BBAXAY
|
Xylocaine (Gel/Injection/Solution) | Lidocaine hydrochloride | Anaesthesia | 7,414 |
|
Lidocaine 100mg/10ml (1%) solution for injection ampoules
1502010J0AABWBW
|
Lidocaine hydrochloride (Local Anaesthesia) | Lidocaine hydrochloride | Anaesthesia | 7,387 |
|
Glycopyrronium bromide 600micrograms/3ml inj ampoules
1501030G0AAABAB
|
Glycopyrronium brom (Pre-med) | Glycopyrronium bromide | Anaesthesia | 6,055 |
|
Versatis 700mg medicated plasters
1502010J0BSAAEL
|
Versatis (Lidocaine hydrochloride) | Lidocaine hydrochloride | Anaesthesia | 4,571 |
|
Hyoscine hydrobromide 400micrograms/1ml inj ampoules
1501030H0AAAAAA
|
Hyoscine hydrob (parent) | Hyoscine hydrobromide | Anaesthesia | 4,381 |
|
Ametop 4% gel
1502010A0BBAAAA
|
Ametop | Tetracaine | Anaesthesia | 3,869 |
|
Lidocaine 2% and Chlorhexidine gel
1502010J0AABQBQ
|
Lidocaine hydrochloride (Local Anaesthesia) | Lidocaine hydrochloride | Anaesthesia | 3,251 |
|
Xylocaine 2% with Adrenaline 100microg/20ml inj vials
1502010J0BBA1A3
|
Xylocaine (Gel/Injection/Solution) | Lidocaine hydrochloride | Anaesthesia | 2,888 |
|
Xylocaine 10mg/dose spray
1502010I0BCABAC
|
Xylocaine (Ointment/Spray) | Lidocaine | Anaesthesia | 2,790 |
|
Lignospan Special 20mg/ml / 12.5micrograms/ml inj 1.8ml cart
1502010J0BTABEN
|
Lignospan Special | Lidocaine hydrochloride | Anaesthesia | 2,728 |
|
Lidocaine 200mg/Adrenaline (base) 100microg/20ml inj vials
1502010J0AAAYAY
|
Lidocaine hydrochloride (Local Anaesthesia) | Lidocaine hydrochloride | Anaesthesia | 2,700 |
|
Lidocaine 4% cream
1502010I0AAAKAK
|
Lidocaine (Local Anaesthesia) | Lidocaine | Anaesthesia | 2,628 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.